Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Genenta Science SpA Sponsored ADR ( (GNTA) ).
On March 12, 2025, Genenta Science S.p.A. entered into a Subscription Agreement with Fondazione Enea Tech e Biomedical for a mandatory convertible bond loan valued at up to €20 million. This financing will support Genenta’s research and development of new therapeutic products, particularly the Temferon cell and gene therapy for renal cancer. The agreement includes issuing bonds in two tranches, with the first tranche issued on March 19, 2025, and the second tranche contingent on specific conditions, including clinical trial progress and regulatory approvals. This strategic move aims to bolster Genenta’s capabilities in advancing its oncology treatments and potentially enhance its market position.
More about Genenta Science SpA Sponsored ADR
Genenta Science S.p.A. is a biotechnology company based in Milan, Italy, specializing in the development of lentivirus-based gene and cell therapies for oncology. The company is active in biotechnological research in the clinical phase and is listed on the Nasdaq Capital Market. Genenta focuses on using gene-based cytokines to activate the immune system within tumors, with a market presence in the United States.
YTD Price Performance: -16.11%
Average Trading Volume: 10,999
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $69.5M
See more data about GNTA stock on TipRanks’ Stock Analysis page.